Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 33 results.
User Information
Export Records
  1. 1.   Transcription factor Tox2 is required for metabolic adaptation and tissue residency of ILC3 in the gut
  2. Das, Arundhoti; Martinez-Ruiz, Gustavo Ulises; Bouladoux, Nicolas; Stacy, Apollo; Moraly, Josquin; Vega-Sendino, Maria; Zhao, Yongge; Lavaert, Marieke; Ding, Yi; Morales-Sanchez, Abigail; Harly, Christelle; Seedhom, Mina O; Chari,Raj; Awasthi, Parirokh; Ikeuchi, Tomoko; Wang, Yueqiang; Zhu, Jinfang; Moutsopoulos, Niki M; Chen, WanJun; Yewdell, Jonathan W; Shapiro, Virginia Smith; Ruiz, Sergio; Taylor, Naomi; Belkaid, Yasmine; Bhandoola, Avinash
  3. Immunity. 2024, May 14; 57(5): 1019-1036.
  1. 2.   Hypoxia, partial EMT and collective migration: Emerging culprits in metastasis
  2. Saxena, Kritika; Jolly, Mohit Kumar; Kuppusamy,Balamurugan
  3. Translational oncology. 2020, NOV; 13(11):
  1. 3.   Vav1 is Essential for HIF-1a Activation via a Lysosomal VEGFR1-Mediated Degradation Mechanism in Endothelial Cells
  2. Hong,Jaewoo; Min,Yongfen; Wuest, Todd; Lin,Charles
  3. Cancers. 2020, JUN; 12(6): E1374.
  1. 4.   The Rho/Rac Guanine Nucleotide Exchange Factor Vav1 Regulates Hif-1 alpha and Glut-1 Expression and Glucose Uptake in the Brain
  2. Hong,Jaewoo; Kim, Yurim; Yanpallewar,Sudhirkumar; Lin,Charles
  3. International journal of molecular sciences. 2020, FEB; 21(4):
  1. 5.   Autocrine IL-10 functions as a rheostat for M1 macrophage glycolytic commitment by tuning nitric oxide production
  2. Baseler, Walter; Davies, Luke; Quigley, L.; Ridnour, Lisa; Weiss, Jonathan; Hussain, S. P.; Wink, David; McVicar, Daniel
  3. Redox biology. 2016, Dec; 10: 12-23.
  1. 6.   C/EBP-delta regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1 alpha
  2. Min, Y.; Ghose, S.; Boelte, K.; Li, J.; Yang, L.; Lin, P. C.
  3. Oncogene. 2011, Dec; 30(49): 4901-4909.
  1. 7.   The tumour suppressor C/EBP delta inhibits FBXW7 expression and promotes mammary tumour metastasis
  2. Balamurugan, K.; Wang, J. M.; Tsai, H. H.; Sharan, S.; Anver, M.; Leighty, R.; Sterneck, E.
  3. Embo Journal. 2010, Dec; 29(24): 4106-4117.
  1. 8.   Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads
  2. Rapisarda, A.; Shoemaker, R. H.; Melillo, G.
  3. Cell Cycle. 2009, Dec; 8(24): 4040-4043.
  1. 9.   Endothelial monocyte activating polypeptide-II modulates endothelial cell responses by degrading hypoxia-inducible factor-1alpha through interaction with PSMA7, a component of the proteasome
  2. Tandle, A. T.; Calvani, M.; Uranchimeg, B.; Zahavi, D.; Melillo, G.; Libutti, S. K.
  3. Experimental Cell Research. 2009 315(11): 1850-1859.
  1. 10.   Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition
  2. Dang, D. T.; Chun, S. Y.; Burkitt, K.; Abe, M.; Chen, S.; Havre, P.; Mabjeesh, N. J.; Heath, E. I.; Vogelzang, N. J.; Cruz-Correa, M.; Blayney, D. W.; Ensminger, W. D.; Croix, B. S.; Dang, N. H.; Dang, L. H.
  3. Cancer Research. 2008 68(6): 1872-1880.
  1. 11.   UVC inhibits HIF-1 alpha protein translation by a DNA damage- and topoisomerase I-independent pathway
  2. Rapisarda, A.; Melillo, G.
  3. Oncogene. 2007, Oct; 26(48): 6875-6884.
  1. 12.   Expression of hypoxia-inducible factor 1 alpha, hypoxia-inducible factor 2 alpha, and von Hippel-Lindau protein in epitheLiaL ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1 alpha is an independent prognostic factor in ovarian carcinoma
  2. Osada, R.; Horiuchi, A.; Kikuchi, N.; Yoshida, J.; Hayashi, A.; Ota, M.; Katsuyama, Y.; Melilo, G.; Konishi, I.
  3. Human Pathology. 2007, Sep; 38(9): 1310-1320.
  1. 13.   The role of ascorbate in the modulation of HIF-1 alpha protein and HIF-dependent transcription by chromium(VI) and nickel(II)
  2. Kaczmarek, M.; Timofeeva, O. A.; Karaczyn, A.; Malyguine, A.; Kasprzak, K. S.; Salnikow, K.
  3. Free Radical Biology and Medicine. 2007, Apr; 42(8): 1246-1257.
  1. 14.   Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1 alpha protein accumulation by NSC 644221
  2. Creighton-Gutteridge, M.; Cardellina, J. H.; Stephen, A. G.; Rapisarda, A.; Uranchimeg, B.; Hite, K.; Denny, W. A.; Shoemaker, R. H.; Melillo, G.
  3. Clinical Cancer Research. 2007, Feb; 13(3): 1010-1018.
  1. 15.   Hypoxic repression of STAT1 and its downstream genes by a pVHL/HIF-1 target DEC1/STRA13
  2. Ivanov, S. V.; Salnikow, K.; Ivanova, A. V.; Bai, L.; Lerman, M. I.
  3. Oncogene. 2007, Feb; 26(6): 802-812.
  1. 16.   Identification of a new natural camptothecin analogue in targeted screening for HIF-1 alpha inhibitors
  2. Klausmeyer, P.; McCloud, T. G.; Melillo, G.; Scudiero, D. A.; Cardellina, J. H.; Shoemaker, R. H.
  3. Planta Medica. 2007, Jan; 73(1): 49-52.
  1. 17.   Hypoxia-inducible factor 1 inhibitors
  2. Melillo, G.
  3. Oxygen Biology and Hypoxia. 2007; 435 : 385-402.
  1. 18.   Crinamine from Crinum asiaticum var.japonicum inhibits hypoxia inducible factor-1 activity but not activity of hypoxia inducible factor-2
  2. Kim, Y. H.; Park, E. J.; Park, M. H.; Badarch, U.; Woldemichael, G. M.; Beutler, J. A.
  3. Biological & Pharmaceutical Bulletin. 2006, Oct; 29(10): 2140-2142.
  1. 19.   Inhibiting hypoxia-inducible factor 1 for cancer therapy
  2. Melillo, G.
  3. Molecular Cancer Research. 2006, Sep; 4(9): 601-605.
  1. 20.   Development of a cell-based reporter assay for screening of inhibitors of hypoxia-inducible factor 2-induced gene expression
  2. Woldemichael, G. M.; Vasselli, J. R.; Gardella, R. S.; McKee, T. C.; Linehan, W. M.; McMahon, J. B.
  3. Journal of Biomolecular Screening. 2006, Sep; 11(6): 678-687.
  1. 21.   Expression of hypoxia inducible factor-1 alpha and 2 alpha in genetically distinct early renal cortical tumors
  2. Kim, C. M.; Vocke, C.; Torres-Cabala, C.; Yang, Y. F.; Schmidt, L.; Walther, M.; Linehan, W. M.
  3. Journal of Urology. 2006, May; 175(5): 1908-1914.
  1. 22.   Targeting topoisomerases to inhibit hypoxia inducible factor 1 (HIF-1): Mechanism and clinical implications
  2. Melillo, G.
  3. Clinical Cancer Research. 2005, DEC 15; 11(24, Part 2 Suppl. S): 9174S-9175S.
  1. 23.   Topotecan inhibits HIF-1 alpha, but not HIF-2 alpha, protein accumulation and tumor growth in human renal cancer cells
  2. Rapisarda, A.; Uranchimeg, B.; Hollingshead, M.; Borgel, S.; Carter, J.; Shoemaker, R. H.; Melillo, G.
  3. Clinical Cancer Research. 2005, DEC 15; 11(24, Part 2 Suppl. S): 9019S-9019S.
  1. 24.   Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity
  2. Kong, D. H.; Park, E. J.; Stephen, A. G.; Calvani, M.; Cardellina, J. H.; Monks, A.; Fisher, R. J.; Shoemaker, R. H.; Melillo, G.
  3. Cancer Research. 2005, OCT 1; 65(19): 9047-9055.
  1. 25.   STRA13 expression and subcellular localisation in normal and tumour tissues: implications for use as a diagnostic and differentiation marker
  2. Ivanova, A.; Liao, S. Y.; Lerman, M. I.; Ivanov, S.; Stanbridge, E. J.
  3. Journal of Medical Genetics. 2005, JUL; 42(7): 565-576.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel